Pfizer lands up to $1.5B from Blackstone to fund obesity drug
What's the deal? Pfizer said on November 11 that Blackstone will provide up to $1.5 billion through 2028 to help fund development of berobenatide, its experimental monthly obesity treatment. The co-funding agreement shifts development costs to Blackstone while leaving Pfizer in control of the program.
How it's structured: Blackstone's potential returns are tied to regulatory and sales milestones. The deal shares the cost and risk of a long clinical program, but the drug remains investigational.
Why now? Pfizer is rebuilding its obesity pipeline after buying Metsera in a roughly $10 billion bidding contest with Novo Nordisk, alongside other licensing and investment deals.
What's the endgame? The market is focused on differentiation, especially convenience and dosing frequency, as Eli Lilly and Novo Nordisk dominate sales and widen access to their drugs. Berobenatide's monthly dosing fits that race.
By the numbers: Measured as a post-IPO debt deal in US health, the financing ranks around the 93rd percentile for size against 1,166 comparable rounds — placing it among the largest of its kind.
The signal: The agreement reflects how drugmakers are sharing the cost and risk of expensive clinical programs with large investors. But it does not establish berobenatide's prospects — Pfizer's obesity ambitions still hinge on clinical results and eventual approval.
Read more: in.marketscreener.com
Image credit: Pfizer
